🔗 Permalink

Inventor profile of:

Robert Schmouder

City:

Berkeley Heights, New Jersey

Country:

United States

Published Applications:

Last publication date:

2026-02-26

Top Assignees for applications by Robert Schmouder

The entities that hold a legal rights for patent applications filed by inventor Schmouder Robert:

NOVARTIS AG 7 Basel, Switzerland

Recent patent applications by Schmouder Robert

Robert Schmouder from Berkeley Heights, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-02-26

US20260053756A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#2 | 2025-08-21

US20250262171A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#3 | 2023-03-23

US20230086687A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#4 | 2022-05-12

US20220142949A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#5 | 2021-01-28

US20210023027A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#6 | 2020-10-22

US20200330407A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#7 | 2020-07-16

US20200222338A1

Human necessities

Dosage regimen of an S1P receptor modulator

#8 | 2020-06-25

US20200197334A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#9 | 2019-11-28

US20190358178A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#10 | 2019-04-25

US20190117593A1

Human necessities

Paediatric Compositions for Treating Multiple Sclerosis

#11 | 2019-03-28

US20190091180A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#12 | 2018-10-11

US20180289638A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#13 | 2018-09-20

US20180263930A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#14 | 2018-09-20

US20180263929A1

Human necessities

Dosage regimen of an S1P receptor modulator

#15 | 2018-06-28

US20180177747A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#16 | 2017-11-23

US20170333368A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#17 | 2017-10-26

US20170304226A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#18 | 2017-07-06

US20170189353A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#19 | 2017-05-11

US20170128389A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#20 | 2016-09-15

US20160263061A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#21 | 2016-09-08

US20160256416A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#22 | 2016-07-21

US20160206574A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#23 | 2016-03-24

US20160081949A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#24 | 2016-01-28

US20160022611A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#25 | 2014-07-03

US20140187516A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#26 | 2014-05-29

US20140148415A1

Chemistry; metallurgy

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#27 | 2014-03-06

US20140066657A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#28 | 2013-09-05

US20130230489A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#29 | 2012-10-18

US20120264719A1

Human necessities

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

#30 | 2011-10-20

US20110257133A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

#31 | 2011-06-23

US20110152380A1

Human necessities

Paediatric Compositions For Treating Multiple Sclerosis

#32 | 2010-06-24

US20100160259A1

Human necessities

DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST

InventorID:

424026 ⎘